Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-BCMA in Relapsed/Refractory Multiple Myeloma
NCT02546167Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Sep 2015
- Primary completion
- Aug 2019
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-BCMA in multiple myeloma (MM) (3 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 2 years. Started Sep 2015; status: completed.
02
Drugs
CART-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02546167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546167.